Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools

D’Anca, Marianna; Fenoglio, Chiara; Buccellato, Francesca R.; Visconte, Caterina; Galimberti, Daniela; Scarpini, Elio

doi:10.3390/cells10071733

Cited by 26 publications

(23 citation statements)

References 113 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bestowing this reason, EVs attract special space for acting both as diagnostic markers and therapeutics in neurodegenerative diseases. The majority of studies observed the role of EVs in both diagnostics and therapeutics ( Candelario and Steindler, 2014 ; Jan et al, 2017 ; Lee and Kim, 2017 ; Izadpanah et al, 2018 ; Hill, 2019 ; Jiang et al, 2019 ; You and Ikezu, 2019 ; Yuan et al, 2019 ; Zhang et al, 2019 , 2021 ; Abdel-Haq, 2020 ; Kapogiannis, 2020 ; Mäger et al, 2020 ; Shaimardanova et al, 2020 ; Vassileff et al, 2020 ; Yin et al, 2020 ; Anakor et al, 2021 ; Cui et al, 2021 ; D’Anca et al, 2021 ; Gagliardi et al, 2021 ; He et al, 2021 ; Jin et al, 2021 ; Manu et al, 2021 ; Toshihide, 2021 ; Upadhya and Shetty, 2021 ; Zhao et al, 2021 ; Picca et al, 2022 ). Notably, 19 studies observed the pioneering role of EVs as a diagnostic biomarker in neurodegenerative diseases ( Table 2 ; Coleman and Hill, 2015 ; Thompson et al, 2016 ; Vella et al, 2016 ; Barreca et al, 2017 ; Chen et al, 2017 ; Li et al, 2018 ; Pluta et al, 2018 ; Ramirez et al, 2018 ; Gámez-Valero et al, 2019 ; Karnati et al, 2019 ; Lee et al, 2019 ; Pluta and Ułamek-Kozioł, 2019 ; Pulliam et al, 2019 ; Vinaiphat and Sze, 2019 ; Banack et al, 2020 ; Guedes et al, 2020 ; Hornung et al, 2020 ; Rani et al, 2020 ; Leggio et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…EVs attract special space for acting both as diagnostic markers and therapeutics in neurodegenerative diseases. The majority of studies observed the role of EVs in both diagnostics and therapeutics (Candelario and Steindler, 2014;Jan et al, 2017;Lee and Kim, 2017;Izadpanah et al, 2018;Hill, 2019;Jiang et al, 2019;You and Ikezu, 2019;Yuan et al, 2019;Zhang et al, 2019Zhang et al, , 2021Abdel-Haq, 2020;Kapogiannis, 2020;Mäger et al, 2020;Shaimardanova et al, 2020;Vassileff et al, 2020;Yin et al, 2020;Anakor et al, 2021;Cui et al, 2021;D'Anca et al, 2021;Gagliardi et al, 2021;He et al, 2021;Jin et al, 2021;Manu et al, 2021; 10.3389/fnmol.2022.1061076 Toshihide, 2021; Upadhya and Shetty, 2021;Zhao et al, 2021;Picca et al, 2022). Notably, 19 studies observed the pioneering role of EVs as a diagnostic biomarker in neurodegenerative diseases (Table 2; Coleman and Hill, 2015;Thompson et al, 2016;Vella et al, 2016;Barreca et al, 2017;Chen et al, 2017;Li et al, 2018;Pluta et al, 2018;Ramirez et al, 2018;Gámez-Valero et al, 2019;Karnati et al, 2019;Lee et al, 2019;Pluta and Ułamek-Kozioł, 2019;…”

Section: Diagnosticmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular vesicles in neurodegenerative diseases: A systematic review

Raghav

Singh

Jeong

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

IntroductionExtracellular vesicles (EVs) are known to have a significant role in the central nervous system (CNS) and neurodegenerative disease.MethodsPubMed, Scopus, ISI Web of Science, EMBASE, and Google Scholar were used to identify published articles about EV modifications (2012 to Feb 2022).ResultsIn total, 1,435 published papers were identified among the searched articles, with 1,128 non-duplicate publications being identified. Following the screening of titles and abstracts, 214 publications were excluded; following the full-text screening of 93 published articles, another 33 publications were excluded. The remaining 60 studies were considered. The kappa statistic of 0.868 indicated that the raters were highly reliable. Furthermore, the inter-reliability and intra-reliability coefficients were found to be 0.931 and 0.908, respectively, indicating strong reliability and consistency between the eligible studies identified by the raters. A total of 27 relevant studies demonstrated the role of EVs as therapeutic and diagnostic biomarkers in neurodegenerative diseases. Of note, 19 and 14 studies, respectively, found EVs to be pioneering in diagnostic and therapeutic roles.DiscussionEVs play an important role in the central nervous system (CNS), aiding in cell-to-cell communication and serving as a diagnostic marker and therapeutic target in a variety of neurodegenerative diseases. EVs are the home of several proteins [including-synuclein (-syn) and tau proteins], lipids, and genetic materials such as DNA and RNA. The presence of novel miRNAs in EVs suggests biomarkers for the diagnosis and screening of neurodegenerative disorders. Furthermore, EVs play an important role in the pathogenesis of such disorders. This systematic review discussed the current state of EVs’ role in neurological diseases, as well as some preclinical studies on the therapeutic and diagnostic potential of EVs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Diagnosticmentioning

confidence: 99%

Extracellular vesicles in neurodegenerative diseases: A systematic review

Raghav

Singh

Jeong

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Detection and characterization of extracellular vesicles might represent, however, a technical challenge [52]. Diagnostic, prognostic, disease, and treatment monitoring values of extracellular vesicles detection, both in CSF and blood, have been proposed for MS [53,54,55,56].…”

Section: Extracellular Vesiclesmentioning

confidence: 99%

Fluid phase biomarkers in multiple sclerosis

Selmaj

Mycko

Furlan

et al. 2022

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewMultiple sclerosis (MS) is highly heterogenic disorder with respect to clinical course, diagnosis, and treatment response. There is an urgent need to search for simply and reliable fluid body biomarker which would assist the diagnosis and prediction of clinical and treatment prognosis.Recent findings 'Traditional' MS biomarkers, with exception of cerebrospinal fluid oligoclonal bands, still are having limited clinical value. Therefore, there is growing interest in novel molecules and ingredients. The most robust results have been generated with regard to cerebrospinal fluid and serum levels of neurofilament light chains (NfL). However, there are still some limitations related to specificity of NfL which delays its use in everyday practice. We present a new approach to search for biomarkers involving extracellular RNA, particularly microRNA (miRNA), and small extracellular vesicles. MiRNA represents an important molecular mechanism influencing gene expression, including those involved in MS pathogenesis and extracellular vesicles transfer multiple cargo, including myelin molecules from parental cells of central nervous system to the long-distance targets. SummaryMiRNAs which control gene expression in cells involved in autoimmune processes in MS as well as extracellular vesicles transferring myelin content might generate a new promising categories of biomarkers of MS.

show abstract

“…Their particular structure may give details regarding a cell's origin and the their pathological mechanism. 57,58 Papers focusing on CSF-EVs found excellent associations with MS disease activity or disability, suggesting that they might have a role in diagnosis. Due to the intrusive process needed to get CSF samples, CSF-EVs do not fulfil the requirement for a widely accessible marker, making them ineffective for tracking illness progression over time.…”

Section: Human Studymentioning

confidence: 99%

“…EVs in CNS may be seen in peripheral fluids because they can cross the blood–brain barrier (BBB). Their particular structure may give details regarding a cell's origin and the their pathological mechanism 57,58 . Papers focusing on CSF‐EVs found excellent associations with MS disease activity or disability, suggesting that they might have a role in diagnosis.…”

Section: Role Of Exosome As a Biomarker In Msmentioning

confidence: 99%

The role and therapeutic applications of exosomes in multiple sclerosis disease

Komlakh

Aghamiri

Farshadmoghadam

2022

Clin Exp Pharma Physio

View full text Add to dashboard Cite

A range of the central nervous system (CNS) and immune cells are affected by multiple sclerosis (MS), a complex autoimmune disease of the CNS. Chronic neuroinflammation, demyelination, and neuronal death are all features of MS, but the disease's molecular mechanisms are unknown. Exosomes are small, membrane-bound extracellular vesicles with a crucial role in cell communication. They are stable in biological fluids and emerge from the cell membrane during endocytic internalization. It might be possible to recognize better the mechanisms involved in the development and progress of illnesses by understanding the variety of exosomal contents and their associated targets, like neurologic disorders. In this review, we sought to bring together important data on the biology of exosomes in MS and highlight discoveries on these nanoparticles' prognostic, diagnostic and therapeutic potential.

show abstract

Extracellular Vesicles in Multiple Sclerosis: Role in the Pathogenesis and Potential Usefulness as Biomarkers and Therapeutic Tools

Cited by 26 publications

References 113 publications

Extracellular vesicles in neurodegenerative diseases: A systematic review

Extracellular vesicles in neurodegenerative diseases: A systematic review

Fluid phase biomarkers in multiple sclerosis

The role and therapeutic applications of exosomes in multiple sclerosis disease

Contact Info

Product

Resources

About